STOCK TITAN

Pheton Holdings (PTHL) to acquire 51% of iTonic via milestone-based equity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Pheton Holdings Ltd entered into a stock purchase agreement to acquire 51% of the outstanding shares of iTonic Corporation, a provider of a home health platform that integrates medication dispensing, supply chain management, virtual care, and patient monitoring. As consideration, Pheton agreed to issue 4,000,000 newly issued Class A ordinary shares and warrants to purchase up to 3,000,000 Class A ordinary shares to the selling shareholders.

The consideration shares will be locked up and released only if iTonic meets agreed performance milestones tied to sales volume and sales revenue, measured quarterly beginning January 1, 2026. The warrants are also subject to milestone-based exercisability. The transaction is subject to customary closing conditions and may not close if those conditions are not satisfied.

The consideration shares, the warrants, and the Class A ordinary shares issuable upon warrant exercise will be issued in a private placement, relying on exemptions from registration under Section 4(a)(2) and Rule 506(b) of Regulation D and Regulation S for offers and sales outside the U.S.

Positive

  • None.

Negative

  • None.

Insights

Pheton plans a majority acquisition of a home health platform using milestone-based equity and warrants.

Pheton Holdings Ltd agreed to buy 51% of iTonic Corporation by issuing 4,000,000 Class A ordinary shares and warrants for up to 3,000,000 additional shares. iTonic operates a home health platform that combines hardware and software for in-home medication delivery and care coordination, suggesting Pheton is expanding into technology-enabled healthcare services rather than paying cash.

The structure ties much of the consideration to performance: the consideration shares are subject to lock-up and will be released only if iTonic meets sales volume and sales revenue milestones measured quarterly from January 1, 2026. The warrants are also milestone-based, so actual dilution depends on iTonic’s future operating performance. The stock-based and contingent nature of the deal limits immediate cash outlay but can increase share issuance over time.

The securities will be issued in an unregistered private placement under Section 4(a)(2), Rule 506(b) of Regulation D, and Regulation S, indicating placement with sophisticated and non-U.S. investors. Closing remains subject to customary conditions, so timing and completion are not guaranteed; forward-looking statements highlight risks such as regulatory approvals, potential legal proceedings related to the SPA, and possible termination events.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2025

 

Commission File Number: 001-42263

 

Pheton Holdings Ltd

 

Room 306, NET Building,

Hong Jun Ying South Road, Chaoyang District,

Beijing, China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒          Form 40-F ☐

 

 

 

 

 

 

Information Contained in this Form 6-K Report

 

Entry into a Material Definitive Agreement.

 

On August 27, 2025, Pheton Holdings Ltd (the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with iTonic Corporation (“Target”) and certain shareholders of the Target (collectively, the “Selling Shareholders”), pursuant to which the Company agreed to acquire, and the Selling Shareholders agreed to sell, 51% of the total outstanding shares of the Target (the “Share Acquisition”). As consideration for the Share Acquisition, the Company agreed to issue to the Selling Shareholders (i) 4,000,000 newly issued Class A ordinary shares of the Company (the “Consideration Shares”), and (ii) warrants to purchase up to 3,000,000 Class A ordinary shares of the Company (the “Warrants”).

 

The Target develops and provides a home health platform with integrated and automated components, including medication dispensing, supply chain management, virtual care, and patient monitoring. The platform combines hardware and software to deliver medications in the home while also supporting care coordination for patients. The Target is making efforts to deploy the platform across a growing national network of patients, supporting daily care and long-term health management.

 

Pursuant to the SPA, the Selling Shareholders agreed to enter into lock-up agreements with respect to the Consideration Shares. The Consideration Shares will be subject to release from lock-up upon the achievement of agreed-upon performance milestones set forth in the SPA, which are tied to sales volume and sales revenue generated by the Target. Such milestones will be measured on a quarterly basis beginning January 1, 2026. The Warrants are likewise subject to milestone-based exercisability, as described in the SPA.

 

The SPA contains customary representations, warranties, and covenants of the parties. The closing of the Share Acquisition is subject to customary closing conditions. 

 

Unregistered Sales of Equity Securities.

 

The information contained under “Entry into a Material Definitive Agreement” of this Report on Form 6-K in relation to the Consideration Shares and the Warrants is incorporated herein by reference.

 

The Consideration Shares and the Warrants, and the Class A ordinary shares issuable upon exercise of the Warrants, are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. Such securities will be issued in reliance on exemptions provided by Section 4(a)(2) and Rule 506(b) of Regulation D thereunder, and pursuant to the exemption provided by Regulation S for offers and sales outside the U.S. 

 

Forward Looking Statements

 

Certain statements in this Report are not historical facts, including, without limitation, statements relating to the Share Acquisition, including the ability to complete, and the timing of completion of, the transactions contemplated by the SPA, including the parties’ ability to satisfy the conditions set forth in the SPA and the possibility of any termination of the SPA and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” “continues,” or similar expressions. Such statements are based upon the current beliefs and expectations of management of the Company. These statements are subject to risks, uncertainties, changes in circumstances, assumptions and other important factors, many of which are outside management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Actual results may differ materially from current expectations because of numerous risks and uncertainties including, among others: (1) the risk that the proposed transaction may not be completed in a timely manner or at all; (2) the risk of legal proceedings that may be instituted against the Company and/or the Selling Shareholders related to the SPA, which may result in significant costs of defense, indemnification and liability; (3) the possibility that any or all of the various conditions to the consummation of the Share Acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Share Acquisition; (4) the occurrence of any event, change or other circumstance that could give rise to the termination of the SPA; (5) the effects of disruption from the transactions on Selling Shareholders’ or the Company’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees and business partners; and (6) conditions beyond Selling Shareholders’ and the Company’s control such as timing of holidays, weather, natural disasters, acts of war or terrorism. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s most recent Annual Report on Form 20-F for the year ended December 31, 2024. The Company’s shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Pheton Holdings Ltd
     
Date: August 29, 2025 By: /s/ Jianfei Zhang
  Name:  Jianfei Zhang
  Title:

Chief Executive Officer and

Chairman of the Board of Directors

 

2

 

FAQ

What transaction did Pheton Holdings Ltd (PTHL) disclose in this Form 6-K?

Pheton Holdings Ltd disclosed that it entered into a Stock Purchase Agreement to acquire 51% of the total outstanding shares of iTonic Corporation, a company that develops and provides a home health platform integrating medication dispensing, supply chain management, virtual care, and patient monitoring.

What consideration is Pheton Holdings Ltd (PTHL) paying to acquire 51% of iTonic Corporation?

As consideration for the 51% stake in iTonic Corporation, Pheton agreed to issue to the selling shareholders 4,000,000 newly issued Class A ordinary shares of Pheton and warrants to purchase up to 3,000,000 Class A ordinary shares of Pheton.

How are the PTHL consideration shares and warrants structured in terms of milestones?

The consideration shares will be subject to lock-up agreements and released only upon achievement of performance milestones tied to iTonic’s sales volume and sales revenue, measured quarterly beginning January 1, 2026. The warrants are also subject to milestone-based exercisability as described in the Stock Purchase Agreement.

Are the PTHL consideration shares and warrants registered under the Securities Act?

No. The consideration shares, the warrants, and the Class A ordinary shares issuable upon exercise of the warrants are not being registered under the Securities Act of 1933 or state securities laws. They will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, and under Regulation S for offers and sales outside the U.S.

What conditions must be met for Pheton Holdings Ltd (PTHL) to complete the iTonic acquisition?

Completion of the share acquisition is subject to customary closing conditions specified in the Stock Purchase Agreement. The forward-looking statements section notes risks including possible failure to complete the transaction, potential legal proceedings related to the SPA, regulatory or governmental delays or refusals, and events that could lead to termination of the SPA.

What business does iTonic Corporation operate, according to Pheton Holdings Ltd (PTHL)?

iTonic Corporation develops and provides a home health platform that integrates automated medication dispensing, supply chain management, virtual care, and patient monitoring. The platform combines hardware and software to deliver medications in the home and support care coordination for patients across a growing national network.
Pheton Holdings

NASDAQ:PTHL

PTHL Rankings

PTHL Latest News

PTHL Latest SEC Filings

PTHL Stock Data

15.38M
7.45M
29.35%
0.12%
6.9%
Medical Devices
Healthcare
Link
China
Beijing